List of Excipients in Branded Drug ROPINIROLE HYDROCHLORIDE

Generic Drugs Containing ROPINIROLE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
NCS HealthCare of KY Inc dba Vangard Labs	ropinirole hydrochloride	0615-7536	ANHYDROUS LACTOSE
NCS HealthCare of KY Inc dba Vangard Labs	ropinirole hydrochloride	0615-7536	CELLULOSE, MICROCRYSTALLINE
NCS HealthCare of KY Inc dba Vangard Labs	ropinirole hydrochloride	0615-7536	CROSCARMELLOSE SODIUM
NCS HealthCare of KY Inc dba Vangard Labs	ropinirole hydrochloride	0615-7536	MAGNESIUM STEARATE
NCS HealthCare of KY Inc dba Vangard Labs	ropinirole hydrochloride	0615-7536	SILICON DIOXIDE
NCS HealthCare of KY LLC dba Vangard Labs	ropinirole hydrochloride	0615-8188	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in ROPINIROLE HYDROCHLORIDE?

# Of NDCs	Excipient
4	ALUMINUM OXIDE
4	ANHYDROUS LACTOSE
2	CARBOXYMETHYLCELLULOSE SODIUM
1	CASTOR OIL
33	CELLULOSE, MICROCRYSTALLINE
1	CI 77891

Ropinirole Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 25, 2026

Ropinirole hydrochloride is a mature, generic small-molecule drug with two established product architectures: immediate-release tablets for Parkinson's disease and restless legs syndrome, and extended-release tablets for Parkinson's disease. The commercial opportunity is not in basic molecule differentiation. It is in low-dose content uniformity, modified-release performance, patient-friendly delivery, manufacturability, and excipient systems that reduce food effects, dose variability, and swallowing burden.

The strongest near-term opportunities are extended-release generics, orally disintegrating or multiparticulate products, low-dose RLS formulations, and cost-optimized global products. Ropinirole has no biosimilar exposure because it is a chemically synthesized small molecule. Its legacy brand patents and market exclusivities have expired or are no longer the primary barrier to entry in the U.S. [1][2]

What is ropinirole hydrochloride and which dosage forms are commercially established?

Ropinirole hydrochloride is a dopamine D2/D3 receptor agonist. FDA-approved uses include:

Product type	Primary indication	Typical commercial form	Regulatory route
Immediate-release ropinirole tablets	Parkinson's disease	Film-coated tablets	ANDA or 505(b)(2)
Immediate-release ropinirole tablets	Moderate-to-severe primary restless legs syndrome	Film-coated tablets	ANDA or 505(b)(2)
Extended-release ropinirole tablets	Parkinson's disease	Once-daily matrix or hydrophilic extended-release tablets	ANDA or 505(b)(2)
Orally disintegrating tablet	Potential Parkinson's disease or RLS use	ODT	505(b)(2), or ANDA if reference-equivalent
Multiparticulate extended-release product	Potential once-daily Parkinson's use	Coated pellets, granules, or capsules	505(b)(2) or ANDA depending on equivalence

The originator products were Requip immediate-release tablets and Requip XL extended-release tablets, both associated with GlaxoSmithKline. The immediate-release product was approved in the late 1990s, while Requip XL was approved in 2008. [3][4]

Ropinirole hydrochloride has a low dose range. Immediate-release strengths historically include 0.25 mg, 0.5 mg, 1 mg, 2 mg and 5 mg. The low active load creates a demanding content-uniformity problem because the tablet may contain only a small fraction of drug substance by weight.

What excipients are used in ropinirole hydrochloride immediate-release tablets?

Commercial immediate-release tablets generally use a conventional direct-compression or wet-granulation system containing a diluent, disintegrant, glidant, lubricant and film coating.

Representative excipient functions are:

Excipient class	Common candidates	Primary function
Diluent	Lactose monohydrate, microcrystalline cellulose	Tablet mass, compressibility and dose distribution
Disintegrant	Croscarmellose sodium, sodium starch glycolate, crospovidone	Rapid tablet breakup
Glidant	Colloidal silicon dioxide	Powder flow and die filling
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection and tooling protection
Binder	Povidone, hydroxypropyl cellulose, pregelatinized starch	Granule strength where wet granulation is used
Film former	Hypromellose	Coating integrity
Plasticizer	Polyethylene glycol	Coating flexibility
Opacifier or colorant	Titanium dioxide, iron oxides	Appearance and strength identification

DailyMed labeling for branded ropinirole products identifies lactose, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide and magnesium stearate as core excipients, with hypromellose-based film coatings and colorants varying by strength. [3]

How should the immediate-release excipient system be optimized?

The main formulation target is reliable content uniformity at the 0.25 mg and 0.5 mg strengths. A low-dose blend can segregate during transfer, hopper residence and tablet compression. Commercial development should therefore prioritize:

1. Ordered mixing or geometric dilution for the active pharmaceutical ingredient.
2. A narrow particle-size distribution for ropinirole hydrochloride.
3. A carrier excipient with predictable density and flow.
4. Minimal lubricant addition and controlled blending time.
5. In-process assay mapping across the tablet press run.
6. Strength-specific formulation controls rather than simple proportional scaling.

Lactose and microcrystalline cellulose provide a proven cost-effective base, but their combination requires control of moisture, particle morphology and compaction behavior. Lactose can support good flow and tablet strength, while microcrystalline cellulose improves compactibility and wicking. The ratio should be selected around the desired manufacturing process rather than copied from the reference product.

Croscarmellose sodium is suitable for rapid breakup, but excessive levels can reduce tablet strength or increase sensitivity to compression force. Crospovidone is a viable alternative where faster water uptake, lower swelling pressure or a different disintegration profile is needed.

Magnesium stearate is commercially standard but can slow wetting and dissolution when overblended. Sodium stearyl fumarate is a potential alternative for formulations requiring shorter lubrication sensitivity or improved dissolution robustness.

What excipients are used in ropinirole hydrochloride extended-release tablets?

Extended-release ropinirole products require a controlled-release matrix or another system that limits drug release over approximately 24 hours. Reference-product labeling identifies a hydrophilic matrix approach using excipients such as hypromellose, lactose, colloidal silicon dioxide and magnesium stearate. [4]

A commercial extended-release architecture may contain:

Functional layer	Candidate excipients	Development objective
Drug-containing matrix	Hypromellose, microcrystalline cellulose, lactose	Hydration and gel formation
Release modifier	High-viscosity hypromellose, ethylcellulose, polymers	Control diffusion and erosion
Processing aid	Colloidal silicon dioxide	Flow and blend uniformity
Lubricant	Magnesium stearate or sodium stearyl fumarate	Compression and ejection
Protective coating	Hypromellose, polyethylene glycol, titanium dioxide	Mechanical protection and identification
Multiparticulate barrier	Ethylcellulose, ammonio methacrylate copolymers	Flexible release control

The commercial challenge is not simply achieving a 24-hour dissolution curve. It is matching the reference product across multiple dissolution conditions while maintaining acceptable pharmacokinetics under fed and fasted states.

Which extended-release excipient strategies offer the best opportunity?

A hydrophilic matrix is usually the lowest-cost platform. It is appropriate for a conventional generic where the objective is reference-equivalent performance. A multiparticulate platform can offer stronger differentiation but increases development, coating and bioequivalence complexity.

Three strategies are commercially relevant:

• High-viscosity hypromellose matrix: lowest manufacturing complexity and generally favorable cost.
• Hydrophilic-hydrophobic combination matrix: greater control over erosion and diffusion, with more demanding process development.
• Coated multiparticulates: potential for lower dose dumping risk and capsule or sprinkle presentation, but higher equipment and quality-control costs.

The formulation should be tested against alcohol exposure, agitation, tablet splitting, crushing and abnormal gastrointestinal conditions. Modified-release products are exposed to dose-dumping concerns if the matrix loses integrity under high ethanol concentrations or mechanical stress. FDA guidance treats these studies as part of the risk assessment for extended-release oral products. [5]

What are the main excipient compatibility risks for ropinirole hydrochloride?

Ropinirole hydrochloride is a low-dose, water-soluble salt. The highest formulation risks are usually process and performance risks rather than severe chemical instability.

Risk	Commercial impact	Mitigation
Blend segregation	Failed content uniformity, batch rejection	Particle-size control, ordered mixing, low-transfer processing
Excessive lubricant blending	Slower dissolution and weaker wetting	Defined lubricant addition and blending endpoint
Moisture variability	Changes in flow, compaction and stability	Controlled water activity and packaging
Lactose interaction risk	Potential degradation concern during storage	Compatibility screening and stability testing
Polymer variability	Dissolution drift in extended-release products	Tight viscosity and substitution-grade specifications
Colorant variation	Strength-identification inconsistency	Standardized coating premixes
Over-compression	Delayed immediate-release dissolution	Compression-force design space
Under-compression	Friability and coating defects	Controlled tensile strength range

Lactose is widely used in the reference product and is commercially attractive. A developer should still conduct binary and multicomponent compatibility studies because low-dose drug substances can show degradation that is difficult to detect in bulk excipient screening. Studies should include accelerated stability, humidity stress, impurity profiling and dissolution after storage.

For global products, excipient selection should also account for nitrosamine risk management, elemental impurities, residual solvents and country-specific excipient acceptance. A simple excipient panel with compendial grades can reduce regulatory friction across the U.S., European Union and major emerging markets.

What formulation patents protect ropinirole hydrochloride products?

The original ropinirole patent estate covered the active compound and its medicinal use. Those rights are expired in the principal commercial jurisdictions. Later intellectual-property activity focused on extended-release delivery, dosage forms, manufacturing processes and specific release profiles.

IP category	Historical relevance	Current commercial effect
Ropinirole compound patents	Protected the original molecule	Expired
Immediate-release tablet patents	Covered dosage forms and use	Generally expired or commercially inactive
Extended-release formulation patents	Covered once-daily delivery and release control	Historically relevant; remaining rights must be checked by jurisdiction and claim scope
Method-of-use patents	Parkinson's disease and RLS treatment claims	Most major legacy rights expired
Manufacturing patents	Granulation, coating or matrix processing	Potentially relevant to freedom to operate
Salt, polymorph or particle patents	Could affect drug-substance sourcing	Requires product-specific review

The FDA Orange Book is the principal source for listed patents and regulatory exclusivity associated with approved products. [1] Patent status should be assessed separately for immediate-release and extended-release products because their formulation histories and listing profiles differ.

A generic developer should not assume that expiration of the original compound patent eliminates all risk. The relevant review includes active formulation claims, method-of-use claims, drug-substance patents, supplier agreements and patents covering coating or multiparticulate manufacturing. The most material distinction is between an ANDA that can rely on reference-product equivalence and a differentiated 505(b)(2) product that may require a separate patent and exclusivity strategy.

When did ropinirole hydrochloride lose market exclusivity?

Ropinirole's principal U.S. market exclusivity has ended. Immediate-release generic competition has been established for years, and extended-release generic products have also entered the market. The molecule is therefore a mature generic opportunity rather than a protected branded asset.

Milestone	Approximate timing
U.S. approval of Requip immediate-release	1997
U.S. approval of Requip XL	2008
Immediate-release patent and exclusivity barriers	Expired before the current generic market
Extended-release patent and exclusivity barriers	No longer the principal U.S. entry barrier
Current market structure	Multiple generic suppliers, with product-specific FDA approvals

The exact entry date, patent challenge history and first-filer status depend on the specific strength and dosage form. FDA approval of one generic strength does not automatically establish approval for every extended-release strength or every delivery technology.

Are there Paragraph IV challenges for ropinirole hydrochloride?

Paragraph IV activity was most relevant during the transition from branded Requip products to generic immediate-release and extended-release products. A Paragraph IV certification alleges that a listed patent is invalid, unenforceable or not infringed. The certification can trigger patent litigation and, for a qualifying first filer, potentially support 180-day generic exclusivity under the Hatch-Waxman framework. [6]

For a current entrant, the practical questions are:

• Whether any Orange Book-listed patent remains unexpired for the target product.
• Whether a listed patent covers the specific strength or dosage form.
• Whether the planned product uses the same release mechanism as the reference product.
• Whether a 505(b)(2) product can avoid a listed patent through a different formulation.
• Whether prior litigation or settlements impose launch restrictions.

A new immediate-release ANDA is more likely to face technical and commercial competition than meaningful patent delay. An extended-release product may encounter more detailed formulation scrutiny, especially if its dissolution profile depends on a patented matrix or coating process.

What is the FDA and Orange Book status of ropinirole hydrochloride?

Ropinirole hydrochloride is an FDA-approved small-molecule prescription drug. Immediate-release and extended-release tablets have established reference products and generic pathways. FDA's Orange Book records approved products, therapeutic-equivalence evaluations, patent listings and exclusivity information. [1]

Immediate-release products generally offer the clearest ANDA opportunity because the dosage form is conventional and the clinical indication is established. Extended-release tablets require more complex comparative dissolution and pharmacokinetic work. The FDA's product-specific guidance and general guidance for modified-release oral dosage forms should govern study design. [5][7]

The regulatory opportunity is strongest where a developer can demonstrate:

• Bioequivalence across the required strengths or a justified biowaiver strategy.
• Matching dissolution under multiple pH and agitation conditions.
• Acceptable fed and fasted pharmacokinetics.
• Robust control of low-dose content uniformity.
• A clean excipient and manufacturing-change history.

What commercial opportunities exist for ropinirole hydrochloride?

Low-cost immediate-release tablets

Immediate-release tablets remain the most accessible opportunity. Manufacturing can use established excipients and standard equipment. Margin pressure is high, so the advantage must come from procurement, yield, packaging efficiency and reliable supply.

Potential customers include hospital systems, government tenders, pharmacy benefit managers and international distributors. Tablet strengths should be prioritized according to market demand rather than automatically reproducing every reference strength.

Extended-release generic tablets

Extended-release ropinirole offers greater technical differentiation and may support better pricing than immediate-release tablets. The opportunity depends on the number of approved competitors, payer substitution and the ability to maintain dissolution consistency across scale.

A formulation using standard hypromellose grades is likely to have the best cost position. A developer using a novel polymer combination may obtain a differentiated product but must justify the additional development cost through pricing, supply contracts or lifecycle management.

Orally disintegrating tablets

An ODT could address Parkinson's patients with dysphagia, fluctuating motor control or difficulty swallowing during off periods. The low dose is favorable for ODT development because tablet mass can remain manageable.

Commercial obstacles include taste masking, friability, moisture sensitivity and the need to establish whether the product is truly bioequivalent or requires a 505(b)(2) pathway. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose and co-processed excipients are candidate systems. Taste masking may require polymer coating or ion-exchange technology, increasing cost.

Sprinkle or multiparticulate products

A capsule containing coated ropinirole multiparticulates could support patients who cannot swallow tablets. It may also permit flexible release engineering. This product has a stronger patient-centered value proposition than a conventional tablet, but it carries greater manufacturing and regulatory complexity.

The labeling must control whether pellets may be opened, chewed or mixed with food. Any food administration instruction becomes part of the product's clinical and regulatory profile.

Fixed-dose or combination products

Ropinirole combination products are less attractive than delivery-system improvements. Parkinson's regimens often contain levodopa, carbidopa, MAO-B inhibitors or other agents, but dose titration is individualized. A fixed-dose combination could limit prescribing flexibility and create a more difficult bioequivalence program.

Which companies are challenging or competing with ropinirole products?

The commercial field consists primarily of generic manufacturers and contract manufacturers rather than active originator competition. FDA-approved generic supply has included multiple companies over time, with availability varying by strength, dosage form and manufacturing site. The key competitive variables are:

• Number of approved suppliers.
• Backorder history.
• API sourcing and dual-source capability.
• Ability to supply all strengths.
• Extended-release manufacturing capacity.
• Retail and institutional contract access.
• Regulatory history and inspection status.

No biosimilar pathway applies. Ropinirole is not a biologic, and biosimilar competition is therefore irrelevant. Competition is based on ANDA approvals, supply reliability and pricing.

What patent and manufacturing barriers affect commercial entry?

The main barriers are technical execution and supply economics rather than basic composition-of-matter patent protection.

A developer should secure:

1. A qualified ropinirole hydrochloride API source with controlled particle size.
2. A validated low-dose blending process.
3. Excipient suppliers with consistent grade and regional availability.
4. Dissolution methods capable of detecting small release differences.
5. Packaging that limits moisture exposure.
6. A manufacturing process that can scale without segregation.
7. Freedom-to-operate clearance for extended-release polymers, coatings and process steps.

Geographic coverage is commercially important. A formulation accepted in the U.S. may require separate filings in the European Union, Canada, Japan, China, Brazil and other markets. Excipient monographs, labeling rules and reference-product requirements differ by jurisdiction. A platform using common compendial excipients can reduce regional variation.

How strong is the patent estate for ropinirole hydrochloride?

The legacy patent estate is weak as a barrier to conventional generic immediate-release entry because the principal molecule and early product protections are old and expired. The estate is more relevant for specific extended-release mechanisms, novel delivery systems and process claims.

Product concept	Patent barrier	Development barrier	Commercial attractiveness
Conventional IR tablet	Low	Low	Moderate, price-driven
High-quality ER tablet	Low to moderate	Moderate	High relative to IR
ODT	Depends on design	Moderate	Moderate
Sprinkle multiparticulates	Depends on design	High	Moderate to high niche value
Novel combination product	Potentially new IP	High	Uncertain
Novel salt or polymorph	Product-specific	Moderate to high	Limited unless clinically useful

The strongest defensible position is likely to come from formulation know-how, manufacturing reliability, packaging, regulatory execution and differentiated patient administration rather than from broad molecule claims.

Key Takeaways

• Ropinirole hydrochloride is a mature generic small molecule with no biosimilar risk.
• Immediate-release tablets use conventional excipients, including lactose, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide and magnesium stearate.
• Low-dose content uniformity is the central immediate-release development risk.
• Extended-release tablets offer the strongest conventional commercial opportunity because they require more technical capability and have greater formulation differentiation.
• Hydrophilic hypromellose matrices provide the most practical cost and regulatory platform for extended-release development.
• ODT and multiparticulate products can address swallowing difficulty but require stronger taste, moisture and bioequivalence strategies.
• Legacy compound and early product patent protection is no longer the principal U.S. market barrier.
• Current freedom-to-operate review should focus on extended-release claims, manufacturing processes, coating systems and jurisdiction-specific Orange Book listings.
• Commercial success will depend more on supply reliability, cost control and differentiated delivery than on broad patent exclusivity.

FAQs About Ropinirole Hydrochloride Formulation and Commercial Entry

Can lactose be used in a generic ropinirole hydrochloride tablet?

Yes. Lactose is used in reference-product formulations and is a practical diluent for immediate-release and some extended-release tablets. Compatibility, moisture and impurity testing remain necessary during development.

Is ropinirole hydrochloride suitable for an orally disintegrating tablet?

Yes. Its low dose is technically favorable for an ODT. The main development issues are taste masking, tablet robustness, moisture protection and demonstrating the appropriate bioequivalence pathway.

What is the best polymer for extended-release ropinirole tablets?

Hypromellose is the most practical starting polymer for a hydrophilic matrix. Its viscosity grade, concentration, particle size and hydration behavior must be optimized against the reference dissolution profile.

Does ropinirole hydrochloride require a biosimilar application?

No. Ropinirole hydrochloride is a chemically synthesized small molecule. U.S. market entry generally proceeds through an ANDA or, for a differentiated product, a 505(b)(2) application.

Is a ropinirole multiparticulate product commercially defensible?

Potentially. Multiparticulates can support sprinkle administration and flexible release control. Their value depends on demonstrated patient benefit, reliable coating performance and a regulatory strategy that supports differentiated labeling.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

3. GlaxoSmithKline. (2010). Requip tablets prescribing information. U.S. Food and Drug Administration.

4. GlaxoSmithKline. (2010). Requip XL extended-release tablets prescribing information. U.S. Food and Drug Administration.

5. U.S. Food and Drug Administration. (2019). Extended release oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations. Center for Drug Evaluation and Research.

6. U.S. Food and Drug Administration. (2017). ANDA submissions: Refuse-to-receive standards. Center for Drug Evaluation and Research.

7. U.S. Food and Drug Administration. (2023). Product-specific guidances for generic drug development. Center for Drug Evaluation and Research.